An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Research in Social and Administrative Pharmacy

• Publication date

  2017-05-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.sapharm.2016.05.042PMID 27263802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting

  2016cited by this paper
• Twopm: Two-Part Models

  2015cited by this paper
• Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey

  2012cited by this paper
• Friction-cost method as an alternative to the human-capital approach in calculating indirect costs

  2012cited by this paper
• Simplifying the estimation of difference in differences treatment effects with Stata

  2012cited by this paper
• Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

  2012cited by this paper
• Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

  2011cited by this paper
• Inflammatory bowel disease‐attributable costs and cost‐effective strategies in the United States: A review

  2011cited by this paper
• What's the Risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression.

  2009cited by this paper
• The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis

  2008cited by this paper
• The costs of Crohn's disease in the United States and other Western countries: a systematic review

  2008cited by this paper
• The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

  2007cited by this paper
• Medical Expenditure Panel Survey (MEPS)

  2005cited by this paper
• Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

  2004cited by this paper
• Management of Crohn's Disease in Adults

  2001cited by this paper
• Annual cost of care for Crohn's disease: a payor perspective

  2000cited by this paper
• A Practical Guide for Calculating Indirect Costs of Disease

  1996cited by this paper
• Inflammatory Bowel Disease: Costs‐of-Illness

  1992cited by this paper
• Non-steroidal anti-inflammatory drugs and the lower gastrointestinal tract.

  1987cited by this paper
• Societal and individual determinants of medical care utilization in the United States.

  1973cited by this paper
• Distributed under Creative Commons Cc-by 4.0 Differences in Healthcare Expenditures for Inflammatory Bowel Disease by Insurance Status, Income, and Clinical Care Setting

  year unknowncited by this paper
• Clinical and Experimental Gastroenterology Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress the Impact of Biologics on Health-related Quality of Life in Patients with Inflammatory Bowel Disease

  year unknowncited by this paper

• Integrating Bioinformatics and Experimental Validation Identifies SCD as a Ferroptosis-Related Immune Regulator and Therapeutic Target in Crohn’s Disease

  2025cites this paper
• Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease

  2024cites this paper
• The hospitalization burden of inflammatory bowel disease in a southwestern highland region of China: a territory-wide study from 2015 to 2020

  2024cites this paper
• A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States

  2023cites this paper
• New Diagnostic Marker for Crohn’s Disease — Ileocecal Lipomatosis

  2023cites this paper
• Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States

  2023cites this paper
• The Role of Oral Probiotics in Alleviating Inflammation, Symptom Relief, and Postoperative Recurrence and Their Side Effects in Adults With Crohn's Disease: A Systematic Review

  2023cites this paper
• Abdominal pain is associated with an increased risk of future healthcare resource utilization in inflammatory bowel disease

  2023cites this paper
• Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis

  2022cites this paper
• Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents

  2022cites this paper
• Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study

  2021cites this paper
• Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

  2021cites this paper
• Metagenomic analysis of primary colorectal carcinomas and their metastases identifies potential microbial risk factors

  2021cites this paper
• Viruses in colorectal cancer

  2021cites this paper
• S945 Racial and Gender Differences in IBD-Related Concerns

  2021cites this paper
• Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn’s Disease

  2021cites this paper
• Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease

  2021cites this paper
• Clinical characteristics and prognostic factors for Crohn’s disease relapses using natural language processing and machine learning: a pilot study

  2021cites this paper
• Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs

  2020cites this paper
• Beneficial effects of Ajuga chamaepitys (L.) Schreber subsp. chia (Schreber) and its iridoids on the colitis model: Histopathological and biochemical evidence.

  2020cites this paper
• Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol

  2020cites this paper
• Canna x generalis L.H. Bailey rhizome extract ameliorates dextran sulphate sodium-induced colitis via modulating intestinal mucosal dysfunction, oxidative stress, inflammation, and TLR4/ NF-ҡB and NLRP3 inflammasome pathways.

  2020cites this paper
• Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study

  2020cites this paper
• The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care

  2020cites this paper
• Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases

  2020cites this paper
• The burden of cost in inflammatory bowel disease: a medical economic perspective.

  2020cites this paper
• Cost‐Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‐Severe Crohn's Disease in Biologic‐Naïve Patients

  2019cites this paper
• Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit

  2019cites this paper
• Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.

  2019cites this paper
• Fragility index: how fragile is the data that support the American College of Gastroenterology guidelines for the management of Crohn’s disease?

  2019cites this paper
• Polyphenol-rich extract of Ocimum gratissimum leaves ameliorates colitis via attenuating colonic mucosa injury and regulating pro-inflammatory cytokines production and oxidative stress.

  2018cites this paper
• The Occurrence of Postoperative Complications in Patients Undergoing Surgery due to Complications from Crohn's Disease: A Case Report

  2018cites this paper
• Crohn's Disease: Diagnosis and Management.

  2018cites this paper
• A medicinal plant compound, capnoidine, prevents the onset of inflammation in a mouse model of colitis.

  2018cites this paper
• Exploring low molecular weight molecules produced by hookworms (Ancylostoma caninum) and their use as anti-inflammatory agents

  2017cites this paper